Skip to main content
Caplight Logo









Currus Biologics

Currus Biologics

Private
MelbourneHealthcare & Life Scienceshttps://www.currusbio.com/

Last Round

Series A

Jun 28, 2021

Total Funding Raised

$7.6M

Company Overview

Currus Biologics is a biotechnology company developing CAR-T cell therapies utilizing its proprietary BEAT technology to treat solid tumor cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapysolid tumor oncologycancer immunotherapybispecific antibodycell therapyimmuno-oncologybiotechnologynext-gen CAR-Tdrug discoveryprecision medicinetumor microenvironmentbiologicspre-clinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Currus Biologics Comparables

Compare Currus Biologics with similar companies based on industry and business-model similarity.

Currus Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Inceptor Bio
81%
Triumvira Immunologics
78%
AffyImmune Therapeutics
78%
View all Comparables

Currus Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 28, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Sam Cobb

Chief Executive Officer

Executive Team

Currus Biologics Investors

Notable investors and investment history

Currus Biologics investors
InvestorRounds
UniseedSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 7, 2025

    Monthly visitors increased 90% MoM, reaching 2.1K.

  • Jun 28, 2021

    $8M round led by Uniseed

View all signals

Currus Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Currus Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Currus Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMelbourne
Employee Range8
Year Founded2021
Last FundingJun 28, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?